<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936596</url>
  </required_header>
  <id_info>
    <org_study_id>OS-1</org_study_id>
    <nct_id>NCT02936596</nct_id>
  </id_info>
  <brief_title>Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome</brief_title>
  <official_title>Biochemical Response of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combination Therapy of Immunosuppressive Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaoli Fan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome
      induced by ursodeoxycholic acid only or combination therapy of immunosuppressive agents
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients that achieve biochemical remission of autoimmune hepatitis(AIH)</measure>
    <time_frame>Month 6 during treatment with ursodeoxycholic acid only or combination therapy of immunosuppressive agents</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase (ALT)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase(AST)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G(IgG)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Globin(GLB)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin(TB)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct bilirubin(DB)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase(ALP)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamyltransferase(GGT)</measure>
    <time_frame>Week 2 and Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Evaluation of side effects during the study period(6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Hepatitis, Autoimmune</condition>
  <condition>Cholangitis</condition>
  <condition>Liver Cirrhosis, Biliary</condition>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid + immunosuppressive agents group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodeoxycholic acid + immunosuppressive agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ursodeoxycholic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid combination of immunosuppressive agents</intervention_name>
    <description>Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)</description>
    <arm_group_label>Ursodeoxycholic acid + immunosuppressive agents group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Ursodeoxycholic Acid</description>
    <arm_group_label>Ursodeoxycholic acid group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Patients aged 18-70 years;

          -  2.Diagnosed with primary biliary cholangitis-autoimmune hepatitis overlap syndrome
             according to Paris criteria, based on liver biopsy results obtained 3 months before
             screening;

          -  3.White blood cell count ≥2.5x10^9/L or platelet count ≥50x10^9/L at inclusion;

          -  4.Agreed to participate in the trial, and assigned informed consent.

        Exclusion Criteria:

          -  1. The presence of hepatitis A, B, C, D, or E virus infection;

          -  2. Patients with indications for immunosuppressive treatment at inclusion: serum
             alanine transaminase(ALT) or aspartate transaminase(AST) ≥10 fold upper limit of
             normal(ULN)，or serum ALT or AST≥ 5 fold ULN and γglobulin level ≥ 2 fold ULN, or
             bridging necrosis or multiacinar necrosis on histological examination.

          -  3. Patients with complications of cirrhosis;

          -  4. Patients with previous treatment of immunosuppressive agents or traditional Chinese
             medicine for more than one month;

          -  5. Primary sclerosing cholangitis,non-alcoholic steatohepatitis,drug induced liver
             disease or Wilson's disease confirmed by liver biopsy;

          -  6. Pregnant and breeding women;

          -  7. Severe disorders of other vital organs, such as severe heart failure, cancer;

          -  8. Parenteral administration of blood or blood products within 6 months before
             screening;

          -  9. Recent treatment with drugs having known liver toxicity;

          -  10.Taken part in other clinic trials within 6 months before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital,Chengdu, Sichuan, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoli Fan, MM</last_name>
    <phone>+862885422311</phone>
    <email>13980433451@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoli Fan, MM</last_name>
      <phone>+8618008028017</phone>
      <email>13980433451@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Yang, MD</last_name>
      <email>yangli_hx@scu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2016</study_first_submitted>
  <study_first_submitted_qc>October 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoli Fan</investigator_full_name>
    <investigator_title>Master Degree</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

